Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers

European Urology

Volumn 62, Issue 5, 2012, Pages 902-909

  Hoeks, Caroline M A ^a   Schouten, Martijn G ^a   Bomers, Joyce G R ^a   Hoogendoorn, Stefan P ^a   Hulsbergen Van De Kaa, Christina A ^a   Hambrock, Thomas ^a   Vergunst, Henk ^b   Sedelaar, J P Michiel ^a   Fütterer, Jurgen J ^a   Barentsz, Jelle O ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Magnetic resonance imaging; Prostate biopsy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

AGED; CHI-SQUARE DISTRIBUTION; HUMANS; IMAGE-GUIDED BIOPSY; KALLIKREINS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; ULTRASONOGRAPHY, INTERVENTIONAL; UP-REGULATION;

EID: 84862533390     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.01.047     Document Type: Article

References (29)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. F.H. Schröder, H.B. Carter, and T. Wolters Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics Eur Urol 53 2008 468 477
3. F.H. Schroder, M.P. van der, and P. Beemsterboer Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 90 1998 1817 1823
4. B. Djavan, V. Ravery, and A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679 1683
5. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol. In press. doi:10.1007/s00345-011-0675-2.
6. T. Franiel, C. Stephan, and A. Erbersdobler Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning Radiology 259 2011 162 172
7. D. Beyersdorff, A. Winkel, B. Hamm, S. Lenk, S.A. Loening, and M. Taupitz MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results Radiology 234 2005 576 581
8. T. Hambrock, D.M. Somford, and C. Hoeks Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen J Urol 183 2010 520 527
9. A.G. Anastasiadis, M.P. Lichy, and U. Nagele MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies Eur Urol 50 2006 738 749
10. K. Engelhard, H.P. Hollenbach, B. Kiefer, A. Winkel, K. Goeb, and D. Engehausen Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device Eur Radiol 16 2006 1237 1243
11. K. Katahira, T. Takahara, and T.C. Kwee Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation Eur Radiol 21 2011 188 196
12. N.B. Delongchamps, M. Rouanne, and T. Flam Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging BJU Int 107 2011 1411 1418
13. P.C. Vos, T. Hambrock, J.O. Barenstz, and H.J. Huisman Computer-assisted analysis of peripheral zone prostate lesions using T2-weighted and dynamic contrast enhanced T1-weighted MRI Phys Med Biol 55 2010 1719 1734
14. T. Hambrock, J.J. Futterer, and H.J. Huisman Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility Invest Radiol 43 2008 686 694
15. P.J. Bastian, L.A. Mangold, J.I. Epstein, and A.W. Partin Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis Cancer 101 2004 2001 2005
16. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114
17. H.U. Ahmed, Y. Hu, and T. Carter Characterizing clinically significant prostate cancer using template prostate mapping biopsy J Urol 186 2011 458 464
18. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer 95 2002 281 286
19. T.A. Stamey, F.S. Freiha, J.E. McNeal, E.A. Redwine, A.S. Whittemore, and H.P. Schmid Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 Suppl 3 1993 933 938
20. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
21. K.A. Roehl, J.A. Antenor, and W.J. Catalona Serial biopsy results in prostate cancer screening study J Urol 167 2002 2435 2439
22. J.-L. Campos-Fernandes, L. Bastien, and N. Nicolaiew Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy Eur Urol 55 2009 600 609
23. S. Roemeling, M.J. Roobol, M.W. Kattan, T.H. van der Kwast, E.W. Steyerberg, and F.H. Schroder Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations Cancer 110 2007 2218 2221
24. S. Ikonen, P. Karkkainen, and L. Kivisaari Magnetic resonance imaging of prostatic cancer: does detection vary between high and low Gleason score tumors? Prostate 43 2000 43 48
25. T. Hambrock, C. Hoeks, and C. Hulsbergen-van de Kaa Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort Eur Urol 61 2012 177 184
26. V. Scattoni, A. Zlotta, R. Montironi, C. Schulman, P. Rigatti, and F. Montorsi Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature Eur Urol 52 2007 1309 1322
27. M.G. Schouten, J.G. Bomers, and D. Yakar Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies Eur Radiol 22 2012 476 483
28. A. De Oliveira, J. Rauschenberg, D. Beyersdorff, W. Semmler, and M. Bock Automatic passive tracking of an endorectal prostate biopsy device using phase-only cross-correlation Magn Reson Med 59 2008 1043 1050
29. P.A. Pinto, P.H. Chung, and A.R. Rastinehad Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging J Urol 186 2011 1281 1285